Cholinesterase (ChE) inhibitors are the only class of drug that have consistently shown improvement in cognitive function in patients with mild to moderate Alzheimer’s disease. Unfortunately, improvement is generally rather small.¹ Recent clinical trials have caused considerable controversy about their actual benefit and indications. On one hand, some studies suggest more extensive use because improvement of cognitive function has also been observed in vascular dementia, dementia with Lewy bodies, and Parkinson’s disease with dementia. However, on the other hand a recent study in community resident patients with mild to moderate Alzheimer’s disease concluded that benefits were “below minimally relevant thresholds.”²

On the …